Becaris
Browse

Supplementary materials: Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients

Download (83.64 kB)
dataset
posted on 2024-11-13, 14:03 authored by Filip Stanicic, Vladimir Zah, Dimitrije Grbic, Debra De Angelo, Wendy Bibeau

These are peer-reviewed supplementary materials for the article 'Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients' published in the Journal of Comparative Effectiveness Research.

  • Table A1: ICD-10-CM codes for chronic PTSD
  • Table A2: ICD-10 CM codes for acute PTSD
  • Table A3: ICD-10-CM codes related to cancer diagnosis
  • Table A4: ICD-10-CM codes related to MDD, bipolar disorder, and schizophrenia
  • Table A5: NDC codes related to FDA-approved medications for PTSD treatment
  • Table A6: Procedure codes related to the psychotherapies used for PTSD management
  • Table A7: ICD-10-CM codes related to anxiety
  • Table A8: Demographic characteristics of the matched population
  • Table A9: Clinical characteristics of the matched population
  • Table A10: Out-of-pocket healthcare costs of PTSD patients during the 2-year follow-up period within the matched population
  • Table A11: Overall healthcare costs of PTSD patients during the 2-year follow-up period within the matched population
  • Table A12: The resource use of PTSD patients during the first year of the follow-up period within the matched population
  • Table A13: Demographic characteristics of PTSD patients with SUD/AUD diagnosis
  • Table A14: Clinical characteristics of PTSD patients with SUD/AUD diagnosis
  • Table A15: Out-of-pocket healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUD
  • Table A16: Overall healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUD
  • Table A17: Resource use during the first year of the follow-up period within the sub-sample of chronic PTSD patients diagnosed with SUD/AUD

Aim: Exploring the healthcare costs and resource use among privately insured US patients with posttraumatic stress disorder (PTSD). Methods: This study used Merative MarketScan data. The index date was defined as the first PTSD claim. Study period included a 1-year pre-index and 2-year post-index follow-up. Cases with only acute PTSD, cancer, or insurance gap during the study period were excluded. The PTSD with (PwC) and PTSD without comorbidities (PwoC) cohorts were defined by the presence/absence of comorbid mental health conditions (schizophrenia, bipolar and major depressive disorder). Baseline PTSD (BP) cohort included PwoC cases with only index PTSD event and without FDA-approved PTSDmedications or psychotherapy. Sub-analysis is conducted among patients with PTSD and substance/alcohol use disorder. Study cohorts were matched in a 1:1:1 ratio. Results: The matched sample included 5076 patients (1681 PwC, 1681 PwoC, 1714 BP). PwC patients had higher 2-year PTSD-related costs than PwoC and BP patients ($3762 vs $1750 and $841; all p < 0.001). The same trend was noted among all-cause and anxiety-related costs. PwC patients had higher 2-year PTSD-related inpatient and emergency department (ED) rates than PwoC (10.2% vs 1.7% and 6.8% vs 2.6%, all p < 0.001) and inpatient and outpatient rates than BP (10.2% vs 2.1% and 98.0% vs 93.1%; all p ≤ 0.004). The sub-analysis had 3776 patients (3154 PwC, 537 PwoC, 85 BP). PwC had higher 2-year PTSD-related costs than PwoC and BP ($7668 vs $2919 and $1,483; all p < 0.001). The same trend was noted in all-cause and anxiety-related costs. PwC also had higher 2-year PTSD-related inpatient and ED rates than PwoC (25.6% vs 10.4% and 12.7% vs 5.2%; all p < 0.001) and inpatient and outpatient rates than BP (25.6% vs 8.2% and 95.5% vs 84.7%; all p < 0.001). Conclusion: PTSD is associated with high healthcare costs and resource use. The highest economic burden was observed in patients with PTSD and mental health comorbidities.

Funding

This work was funded with support from Lykos Therapeutics.

History